Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Richard Smykla"'
Autor:
Satu Mustjoki, Francis Y.F. Lee, Kimmo Porkka, Panu E. Kovanen, Akseli Hemminki, Leena Saikko, Siri Tähtinen, Paula Savola, Markus Vähä-Koskela, Richard Smykla, Erin Michaud, Jun Yan, Mette Ilander, Can Hekim
Supplementary Figure S1. Dasatinib-induced rapid lymphocyte mobilization and tumor growth rate correlation Supplementary Figure S2. Immunohistochemical staining of CD8+ T cells in the tumor tissues of A) vehicle treated control group and B) dasatinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a61dbd4a204cf319008e6f53370ac729
https://doi.org/10.1158/2326-6066.22537601
https://doi.org/10.1158/2326-6066.22537601
Autor:
Satu Mustjoki, Francis Y.F. Lee, Kimmo Porkka, Panu E. Kovanen, Akseli Hemminki, Leena Saikko, Siri Tähtinen, Paula Savola, Markus Vähä-Koskela, Richard Smykla, Erin Michaud, Jun Yan, Mette Ilander, Can Hekim
Dasatinib, a broad-range tyrosine kinase inhibitor, induces rapid mobilization of lymphocytes and clonal expansion of cytotoxic cells in leukemia patients. Here, we investigated whether dasatinib could induce beneficial immunomodulatory effects in so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34d227dfbe88af5b297188037bd5ef6c
https://doi.org/10.1158/2326-6066.c.6548492.v1
https://doi.org/10.1158/2326-6066.c.6548492.v1
Autor:
Kimmo Porkka, Akseli Hemminki, Satu Mustjoki, Jun Yan, Richard Smykla, Francis Y. Lee, Markus Vähä-Koskela, Mette Ilander, Siri Tähtinen, Can Hekim, Leena Saikko, Paula Savola, Panu E. Kovanen, Erin Michaud
Publikováno v:
Cancer immunology research. 5(2)
Dasatinib, a broad-range tyrosine kinase inhibitor, induces rapid mobilization of lymphocytes and clonal expansion of cytotoxic cells in leukemia patients. Here, we investigated whether dasatinib could induce beneficial immunomodulatory effects in so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d98145853e0bd4a5ed61f82ebf98b17
https://pubmed.ncbi.nlm.nih.gov/28073775
https://pubmed.ncbi.nlm.nih.gov/28073775
Autor:
Teresa Melo, Frank Lee, A-M Lahesmaa-Korpinen, Kimmo Porkka, Sari Hernesniemi, Philippe Rousselot, Kaisa Auvinen, Jalkanen S, Anna Kreutzman, Mathieu Molimard, Sampsa Hautaniemi, Satu Mustjoki, Marko Salmi, Jukka Vakkila, Stéphane Bouchet, Richard Smykla
Publikováno v:
Leukemia. 27:914-924
Tyrosine kinase inhibitors (TKIs) have potent effects on malignant cells, and they also target kinases in normal cells, which may have therapeutic implications. Using a collection of 55 leukemia patients treated with TKI therapy (chronic myeloid leuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de183da18d7541577cec70aacec103f9
https://doi.org/10.1038/leu.2012.348
https://doi.org/10.1038/leu.2012.348
Autor:
Francis Y. Lee, Richard Smykla, Robert M. Borzilleri, Craig R. Fairchild, Gregory D. Vite, Amrita Kamath, Robert Kramer
Publikováno v:
Cancer Chemotherapy and Pharmacology. 63:157-166
The epothilones and their analogs constitute a novel class of antineoplastic agents, produced by the myxobacterium Sorangium cellulosum. These antimicrotubule agents act in a similar manner to taxanes, stabilizing microtubules and resulting in arrest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f20a6f138a56b9a72887d30ba55d74
https://doi.org/10.1007/s00280-008-0724-8
https://doi.org/10.1007/s00280-008-0724-8
Autor:
Martin Höglund, C. Michel Zwaan, Henrik Hjorth-Hansen, Rafael F. Duarte, Kimmo Porkka, Suhag Parikh, Benoit Brethon, Robert A. Wild, Satu Mustjoki, Håvar Knutsen, Tuija Lundán, Erkki Elonen, Hervé Dombret, Finella Brito-Babapulle, Hana Klamova, Lydia Eccersley, Montserrat Arnan, Roger Luo, Richard Smykla, Johanna Rimpiläinen, Franz Gruber, Ron Paquette, Emmanuel Raffoux, Perttu Koskenvesa, Francis Y. Lee
Publikováno v:
Blood, 112(4), 1005-1012. American Society of Hematology
Although imatinib, a BCR-ABL tyrosine kinase inhibitor, is used to treat acute Philadelphia chromosome–positive (Ph+) leukemia, it does not prevent central nervous system (CNS) relapses resulting from poor drug penetration through the blood-brain b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ceedc511a7965b3b88d994b5223378f
https://pure.eur.nl/en/publications/13a0aaaf-c56a-4ff5-893d-cc0e4742a4ad
https://pure.eur.nl/en/publications/13a0aaaf-c56a-4ff5-893d-cc0e4742a4ad
Autor:
Jennifer K. Peterson, Francis Y.F. Lee, Pamela J. Cheshire, Jeremy Creech, Richard Smykla, Chandra Tucker, Catherine A. Billups, Edward Favours, Peter J. Houghton
Publikováno v:
Clinical Cancer Research. 11:6950-6958
Purpose: Vinca alkaloids, agents that cause depolymerization of microtubules, are highly active in treatment of many pediatric cancers. In contrast, taxanes, agents that stabilize microtubules, are far less effective against the same cancer types. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b44f6260ecab34fc1bfec89f768fd288
https://doi.org/10.1158/1078-0432.ccr-05-0740
https://doi.org/10.1158/1078-0432.ccr-05-0740
Autor:
Feng Roger Luo, Robert A. Wild, Anne Blackwood-Chirchir, Francis Y. Lee, Holly Palme, Yu Chen Barrett, Amy Camuso, Richard Smykla, Zheng Yang, Susan Galbraith, Krista Fager, Mei-Li Wen, Kelly McGlinchey
Publikováno v:
Cancer chemotherapy and pharmacology. 62(6)
Dasatinib (BMS-354825) is a potent, oral multi-targeted kinase inhibitor. It is an effective therapy for patients with imatinib-resistant or -intolerant Ph+ leukemias,. It has demonstrated promising preclinical anti-tumor activity, and is under clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79448555c9793d95601df5fba937a33d
https://pubmed.ncbi.nlm.nih.gov/18301894
https://pubmed.ncbi.nlm.nih.gov/18301894
Autor:
Brian E. Fink, Tai W. Wong, Hongjian Zhang, Harold Mastalerz, John T. Hunt, Simone Oppenheimer, Gregory D. Vite, Chiang Yu, Richard Smykla, Francis Y.F. Lee, Ashvinikumar V. Gavai, Feng R. Luo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(20 Pt 1)
Purpose: The studies described here are intended to characterize the ability of BMS-599626, a small-molecule inhibitor of the human epidermal growth factor receptor (HER) kinase family, to modulate signaling and growth of tumor cells that depend on H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb8792e492f34e5f154b01190eaf3b47
https://pubmed.ncbi.nlm.nih.gov/17062696
https://pubmed.ncbi.nlm.nih.gov/17062696
Autor:
Tai Wai Wong, John T. Hunt, Chiang Yu, Louis J. Lombardo, Veeraswamy Manne, Gregory D. Vite, David Bol, Richard Smykla, Francis Y.F. Lee, Craig R. Fairchild, Johnni Gullo-Brown, Mei-Li D. Wen
Publikováno v:
Cancer research. 64(11)
BMS-214662 and BMS-225975 are tetrahydrobenzodiazepine-based farnesyltransferase inhibitors (FTIs) that have nearly identical structures and very similar pharmacological profiles associated with farnesyltransferase (FT) inhibition. Despite their simi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::992ad748e5a541ad87c67e08ad0252e3
https://pubmed.ncbi.nlm.nih.gov/15173010
https://pubmed.ncbi.nlm.nih.gov/15173010